| Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system S Riethdorf, H Fritsche, V Müller, T Rau, C Schindlbeck, B Rack, ... Clinical cancer research 13 (3), 920-928, 2007 | 1564 | 2007 |
| Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ... New England Journal of Medicine 382 (7), 597-609, 2020 | 1075 | 2020 |
| A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors M Filipits, M Rudas, R Jakesz, P Dubsky, F Fitzal, CF Singer, O Dietze, ... Clinical Cancer Research 17 (18), 6012-6020, 2011 | 787 | 2011 |
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 … SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ... The Lancet Oncology 21 (4), 519-530, 2020 | 616 | 2020 |
| Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2–overexpressing breast … M Untch, PA Fasching, GE Konecny, S Hasmüller, A Lebeau, ... Journal of Clinical Oncology 29 (25), 3351-3357, 2011 | 604 | 2011 |
| Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial S Riethdorf, V Müller, L Zhang, T Rau, S Loibl, M Komor, M Roller, ... Clinical cancer research 16 (9), 2634-2645, 2010 | 585 | 2010 |
| Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer C Roth, B Rack, V Müller, W Janni, K Pantel, H Schwarzenbach Breast Cancer Research 12, 1-8, 2010 | 525 | 2010 |
| Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity V Müller, N Stahmann, S Riethdorf, T Rau, T Zabel, A Goetz, F Jänicke, ... Clinical Cancer Research 11 (10), 3678-3685, 2005 | 511 | 2005 |
| Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial NU Lin, V Borges, C Anders, RK Murthy, E Paplomata, E Hamilton, ... Journal of Clinical Oncology 38 (23), 2610, 2020 | 411 | 2020 |
| HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial T Fehm, V Müller, B Aktas, W Janni, A Schneeweiss, E Stickeler, ... Breast cancer research and treatment 124, 403-412, 2010 | 407 | 2010 |
| Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial E Hahnen, B Lederer, J Hauke, S Loibl, S Kröber, A Schneeweiss, ... JAMA oncology 3 (10), 1378-1385, 2017 | 405 | 2017 |
| Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study F Amant, G von Minckwitz, SN Han, M Bontenbal, AE Ring, J Giermek, ... Journal of Clinical Oncology 31 (20), 2532-2539, 2013 | 383 | 2013 |
| The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. MM Montano, V Müller, A Trobaugh, BS Katzenellenbogen Molecular endocrinology 9 (7), 814-825, 1995 | 380 | 1995 |
| Treatment of breast cancer during pregnancy: an observational study S Loibl, SN Han, G von Minckwitz, M Bontenbal, A Ring, J Giermek, ... The lancet oncology 13 (9), 887-896, 2012 | 372 | 2012 |
| A clinically relevant gene signature in triple negative and basal-like breast cancer A Rody, T Karn, C Liedtke, L Pusztai, E Ruckhaeberle, L Hanker, R Gaetje, ... Breast cancer research 13, 1-12, 2011 | 366 | 2011 |
| Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients C Eichelser, I Stückrath, V Müller, K Milde-Langosch, H Wikman, K Pantel, ... Oncotarget 5 (20), 9650, 2014 | 360 | 2014 |
| Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials G von Minckwitz, M Untch, E Nüesch, S Loibl, M Kaufmann, S Kümmel, ... Breast cancer research and treatment 125, 145-156, 2011 | 340 | 2011 |
| Breast cancer brain metastases: biology and new clinical perspectives I Witzel, L Oliveira-Ferrer, K Pantel, V Müller, H Wikman Breast cancer research 18, 1-9, 2016 | 310 | 2016 |
| Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials FC Bidard, T Fehm, M Ignatiadis, JB Smerage, C Alix-Panabières, ... Cancer and Metastasis Reviews 32 (1), 179-188, 2013 | 278 | 2013 |
| A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors M Schmidt, B Hellwig, S Hammad, A Othman, M Lohr, Z Chen, D Boehm, ... Clinical cancer research 18 (9), 2695-2703, 2012 | 268 | 2012 |
sibylle loiblProfessor for medicineVerified email at gbg.de
